StreetInsider.com News Articles

Form 144 Guardant Health, Inc. Filed by: Tariq Musa

Fri, 16 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27197892.html

Form 4 Guardant Health, Inc. For: Oct 14 Filed by: Azar Alex M II

Thu, 15 Oct 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20261015/27194371.html

PTAB again upholds TwinStrand patent challenged by Guardant Health

Thu, 15 Oct 2026 16:02:21 -0400

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has issued a second ruling in favor of the University of Washington and TwinStrand Biosciences, rejecting Guardant Health's (Nasdaq: GH) challenge to all 30 claims of U.S. Patent No. 10,760,127, according to a statement from TwinStrand.

The Oct. 14, 2026, Final Written Decision came on remand from the U.S. Court of Appeals for the Federal Circuit, which in January 2026 had directed the PTAB to reconsider the challenge under a different legal framework. Applying that framework, the PTAB again determined that Guardant Health failed to establish the unpatentability of

PTAB again upholds TwinStrand patent challenged by Guardant Health

Thu, 15 Oct 2026 16:02:21 -0400

TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent

Thu, 15 Oct 2026 16:01:00 -0400

Following Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health

SEATTLE--(BUSINESS WIRE)-- TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (Nasdaq: GH) challenge to a core patent underlying Duplex Sequencing. In an Oct. 14, 2026, Final Written Decision on remand from the U.S. Court of Appeals for the Federal Circuit, the PTAB ruled in favor of

TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent

Thu, 15 Oct 2026 16:01:00 -0400

Following Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

Thu, 15 Oct 2026 08:05:00 -0400

Modeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing
New data demonstrates notable screening adherence rate of 99% in medically-underserved populations for Shield blood-based colorectal cancer (CRC) screening test

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee.

A modeling study

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

Thu, 15 Oct 2026 08:05:00 -0400

Modeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing
New data demonstrates notable screening adherence rate of 99% in medically-underserved populations for Shield blood-based colorectal cancer (CRC) screening test

A modeling study

Form 144 Guardant Health, Inc. Filed by: Azar Alex M II

Wed, 14 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27187070.html

Form 4 Guardant Health, Inc. For: Oct 12 Filed by: Azar Alex M II

Tue, 13 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261013/27181917.html

Guardant Health (GH) PT Raised to $200 at Morgan Stanley

Tue, 13 Oct 2026 08:24:09 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Guardant Health (NASDAQ: GH) to $200.00 (from $185.00) while maintaining a Overweight rating.

Guardant Health wins European approval for breast cancer companion diagnostic

Thu, 08 Oct 2026 16:12:48 -0400

Guardant Health (NASDAQ: GH) announced that its Guardant360 CDx liquid biopsy test has received CE-marking under Europe's In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant), a treatment for estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer.

The test detects ESR1 mutations in tumors through a blood draw and is intended to identify patients who may benefit from treatment with camizestrant, an oral selective estrogen receptor degrader. The European approval follows earlier regulatory clearances for the same companion diagnostic use in the United States and Japan.

According to the company's press release, this marks Guardant

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

Thu, 08 Oct 2026 16:12:00 -0400

Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies
This latest approval marks Guardant’s 31st CDx approval

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist. Approval in Europe

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

Thu, 08 Oct 2026 16:12:00 -0400

Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies
This latest approval marks Guardant’s 31st CDx approval

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 08 Oct 2026 16:05:00 -0400

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 08 Oct 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on

Guardant Health (GH) PT Raised to $220 at Baird

Thu, 08 Oct 2026 07:23:16 -0400

Baird analyst Catherine Schulte raised the price target on Guardant Health (NASDAQ: GH) to $220.00 (from $210.00) while maintaining a Outperform rating.

Guardant Health (GH) PT Raised to $220 at Barclays

Wed, 07 Oct 2026 03:50:02 -0400

Barclays analyst Luke Sergott raised the price target on Guardant Health (NASDAQ: GH) to $220.00 (from $200.00) while maintaining a Overweight rating.

Guardant Health study links liquid biopsy test to melanoma recurrence risk

Mon, 05 Oct 2026 11:46:52 -0400

Guardant Health (Nasdaq: GH) announced that Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study, evaluating the company's Guardant Reveal blood test for molecular residual disease (MRD) detection in patients with resected stage II–III melanoma.

The study analyzed 280 longitudinal surveillance samples from 48 patients treated with surgery. According to the published findings, detection of circulating tumor DNA (ctDNA) following surgery was associated with recurrence and melanoma-related death. The test detected 81% of distant recurrences, with 100% specificity in post-treatment samples from patients who remained recurrence-free. ctDNA detection preceded clinical identification

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Mon, 05 Oct 2026 11:27:00 -0400

First published prospective, multicenter study of Guardant Reveal in resected melanoma demonstrates 81% sensitivity for distant recurrence and 100% post-treatment specificity
Molecular residual disease detection approximately four weeks after surgery was independently associated with an approximately 12-fold increased risk of recurrence and a greater than 30-fold increased risk of death

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free,

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Mon, 05 Oct 2026 11:27:00 -0400

First published prospective, multicenter study of Guardant Reveal in resected melanoma demonstrates 81% sensitivity for distant recurrence and 100% post-treatment specificity
Molecular residual disease detection approximately four weeks after surgery was independently associated with an approximately 12-fold increased risk of recurrence and a greater than 30-fold increased risk of death

Form 4 Guardant Health, Inc. For: Oct 01 Filed by: Saia John G.

Fri, 02 Oct 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27143347.html

Form 4 Guardant Health, Inc. For: Oct 01 Filed by: Kalia Kumud

Fri, 02 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27143323.html

Form 4 Guardant Health, Inc. For: Oct 01 Filed by: Monroe Terilyn J.

Fri, 02 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27143341.html

Form 4 Guardant Health, Inc. For: Oct 01 Filed by: Chudova Darya

Fri, 02 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261002/27143289.html